Efficacy/Effectiveness, Safety and Treatment Persistence of Filgotinib in Rheumatoid Arthritis: A Narrative Review of Clinical Trials and Real-World Evidence

Abstract Filgotinib (FIL) is a Janus kinase preferential inhibitor, classified as a targeted synthetic disease-modifying anti-rheumatic drug (tsDMARD). It is approved for patients with rheumatoid arthritis (RA) who have failed treatment with methotrexate (MTX), a conventional synthetic DMARD (csDMAR...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Yoshiya Tanaka, Peter C. Taylor, Jeffrey A. S. Ritsema, Akira Kondo, Toshihiko Kaise
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	Adis, Springer Healthcare 2026-03-01
סדרה:	Rheumatology and Therapy
נושאים:	Rheumatoid arthritis Janus kinase 1 inhibitor Filgotinib Clinical trials Real-world evidence Safety
גישה מקוונת:	https://doi.org/10.1007/s40744-026-00828-3
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!